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EML4-ALK fusion lung cancer: a rare acquired event
Abstract
A recurrent gene fusion between EML4 and ALK in 6.7% of non-small cell lung cancers (NSCLCs) and
NKX2-1 (TTF1, TITF1) high-level amplifications in 12% of adenocarcinomas of the lung were
independently reported recently. Because the EML4-ALK fusion was only shown by a reverse
transcription-polymerase chain reaction approach, we developed fluorescent in situ hybridization assays
to interrogate more than 600 NSCLCs using break-apart probes for EML4 and ALK. We found that
EML4-ALK fusions occur in less than 3% of NSCLC samples and that EML4 and/or ALK
amplifications also occur. We also observed that, in most cases in which an EML4/ALK alteration is
detected, not all of the tumor cells harbor the lesion. By using a detailed multi-fluorescent in situ
hybridization probe assay and reverse transcription-polymerase chain reaction, we have evidence that
other, more common mechanisms besides gene inversion exist including the possibility of other fusion
partners for ALK and EML4. Furthermore, we confirmed the NKX2-1 high-level amplification in a
significant subset of NSCLC and found this amplification to be mutually exclusive to ALK and EML4
rearrangements.
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A recurrent gene fusion between EML4 and ALK in 6.7% of non–small cell lung cancers (NSCLCs) and NKX2-1
(TTF1, TITF1) high-level amplifications in 12% of adenocarcinomas of the lung were independently reported recently.
Because the EML4-ALK fusion was only shown by a reverse transcription–polymerase chain reaction approach, we
developed fluorescent in situ hybridization assays to interrogate more than 600 NSCLCs using break-apart probes
for EML4 and ALK. We found that EML4-ALK fusions occur in less than 3% of NSCLC samples and that EML4 and/
or ALK amplifications also occur. We also observed that, in most cases in which an EML4/ALK alteration is de-
tected, not all of the tumor cells harbor the lesion. By using a detailed multi–fluorescent in situ hybridization probe
assay and reverse transcription–polymerase chain reaction, we have evidence that other, more common mecha-
nisms besides gene inversion exist including the possibility of other fusion partners for ALK and EML4. Further-
more, we confirmed the NKX2-1 high-level amplification in a significant subset of NSCLC and found this
amplification to be mutually exclusive to ALK and EML4 rearrangements.
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The paucity of recurrent gene fusions in common epithelial malig-
nancies may be due to an inability to discover these events rather
than any true lack of such events [1]. Supporting this is the recent
discovery that the majority of prostate cancers harbor a TMPRSS2-
ETS fusion [2]. Finding yet unidentified recurrent rearrangements in
other common epithelial cancers could provide important insights
into carcinogenesis and accelerate rational drug design.
Soda et al. [3] described a novel recurrent gene fusion between ALK
(2p23) and EML4 (2p21) in 5 (6.7%) of 75 non–small cell lung can-
cer (NSCLC) cases. Using an in vitro model, they demonstrated fusion
of the kinase domain of ALK to a poorly characterized gene, EML4, to
generate an oncogenic fusion (EML4-ALK ). ALK, the anaplastic lym-
phoma kinase, has been previously observed to fuse with nucleophos-
min (NPM ) and multiple alternative partner genes in anaplastic large
cell lymphoma [4]. The resulting highly expressed fusion proteins pos-
sess constitutive kinase activity and transforming capacity.
An intriguing but unexplained result was their finding that wild-
type ALK mRNA was detected in one third of all NSCLCs. They
suggested that simple inversion generated the EML4-ALK fusion
gene (ALK and EML4 are 12 Mb apart with opposite orientations).
However, more complex cytogenetic events could be at play, but may
have been overlooked, because of the lack of an in situ analysis. To
resolve this, we developed break-apart fluorescent in situ hybridiza-
tion (FISH) assays for EML4 and ALK (Figure 1A) and analyzed two
population-based NSCLC cohorts from Switzerland and the USA. An-
other recently reported recurrent genetic alteration is the high-level
amplification of NKX2-1 (TTF1) in 12% of adenocarcinomas of the
lung [5]. Using the same cohorts, we validated the recently reported
NKX2-1 high-level amplification in lung cancers and assessed for cor-
relation with EML4 and ALK alterations.Figure 1. Schematic design of the break-apart FISH assays and exe
EML4 and ALK. (B) Loss of DNA on 2p outside the area encoding E
telomeric of ALK ). (C) Loss of interstitial DNA between EML4 and AL
ALK ). (D) Break-apart of ALK (wild-type allele as one yellow, and on
Cluster-like amplification of the ALK focus (multiple yellow signals).Material and Methods
Fluorescent In Situ Hybridization Assays
To assess for rearrangements of both the EML4 and ALK loci, two
unique break-apart FISH assays were designed (because of the prox-
imity of both genes, a fusion assay was not discriminative). For each
gene, two bacterial artificial chromosome (BAC) FISH probes were
created to hybridize with the neighboring centromeric and telomeric
regions of each gene. BAC clones were selected from the March 2006
build of the human Genome using the University of California, Santa
Cruz Genome Browser and were obtained from the BACPAC Re-
source Center (CHORI, Oakland, CA). For EML4, the centromeric
BAC clone was biotin-14-deoxycytidine triphosphate (dCTP)–labeled
RP11-368J11 (eventually conjugated to produce a red signal), and the
telomeric BAC clone was digoxigenin-dUTP–labeled RP11-142M12
(eventually conjugated to produce a green signal). For ALK, the cen-
tromeric BAC clone was biotin-14-dCTP–labeled RP11-993C21
(red), and the telomeric BAC clone was digoxigenin-dUTP–labeled
RP11-984I21 (green) (Figure 1A).
To assess for NKX2-1 (TTF1) amplification, the same FISH assay
as described previously was applied [5]. In brief, a probe spanning the
NKX2-1 gene locus (chr14q13.3) and a reference probe spanning a
stable region in carcinomas of the lung on chromosome (chr14q24.1)
were used. For the NKX2-1 target probe, the biotin-14-dCTP–labeled
BAC clone RP11-1083E2 (eventually conjugated to produce a red sig-
nal), and for the reference probe, the digoxin-dUTP–labeled BAC
clone RP11-72J8 (eventually conjugated to produce a green signal)
were applied as probes.
All samples were analyzed under a ×60 oil immersion objective
using a fluorescence microscope (Olympus, Center Valley, PA)
equipped with appropriate filters, a charge-coupled device camera,mplary findings. (A) Schematic of the break-apart FISH assays for
ML4 and ALK (exemplary for ALK: loss of the green-labeled probe
K (exemplary for ALK: loss of the red-labeled probe centromeric of
e single red and green probe signal for the rearranged allele). (E)
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Imaging, San Jose, CA). Evaluation of the tests was independently per-
formed by two evaluators (S.P. and P.W.). For each case, we attempted
to analyze at least 100 nuclei. We experienced no significant differ-
ences between the two independent evaluations.
Detailed Fluorescent In Situ Hybridization Procedure
Escherichia coli containing the selected BACs were cultured over-
night at 37°C on LB agar (Fisher Scientific, Hampton, NH). Single
clones were selected and grown overnight at 37°C in LB broth (Fisher
Scientific) in an incubator under constant shaking. BACs were selec-
tively extracted from the cultures using Qiagen MiniPrep buffers (P1
with RNaseA, P2 and P3; Germantown, MD). Extracted BACs were
precipitated with isopropyl alcohol and washed with 70% ethanol be-
fore resuspension in distilled, nuclease-free water. Resulting samples
were amplified using the Repli-g Midi kit (Qiagen). Amplified BACs
were labeled using the BioPrime DNA labeling system (Invitrogen,
Carlsbad, CA) to incorporate biotin-14-dCTP into the target probes
(eventually detected by streptavidin, Alexa Fluor 594 conjugate from
Invitrogen) and digoxigenin-11-dUTP (Roche Applied Science, Nutley,
NJ) into the reference probe (eventually detected by Anti-Digoxigenin,
F′ab fragments from Roche Applied Science). Before cell line/tissue
analysis, the integrity and purity of all probes were verified by hy-
bridization to normal peripheral lymphocyte metaphase spreads (Vysis,
Abbott Park, IL).
After deparaffinization, tissue samples were pretreated at 94°C in
Tris/EDTA, pH 7.0, buffer for 0.5 hours before protein digestion
with Zymed Digest-All (Invitrogen) and ethanol dehydration. After
codenaturation of the probe and sample (3 minutes at 94°C for
formalin-fixed paraffin-embedded (FFPE) tissue samples and 3.5 min-
utes at 85°C for cell lines), slides were immediately placed in a dark
moist chamber to hybridize for at least 16 hours at 37°C. After in-
cubation, samples were washed for 5 minutes at 75°C in 0.5× SSC
buffer. Samples were washed three times for 10 minutes with PBS-T
(PBS with 0.025% Tween-20) at room temperature. Blocking was
performed in a dark, moist chamber with CAS-Block (Invitrogen) con-
taining 10% goat serum (Invitrogen) for 10 minutes. Secondary de-
tectors were diluted 1:500 in a blocking reagent, and samples were
incubated for 1 hour at room temperature. Samples were washed three
times with PBS-T buffer as above before mounting with Prolong Gold
Antifade Reagent with DAPI (Invitrogen).
RNA Extraction and Reverse Transcription–Polymerase
Chain Reaction
Three FFPE biopsy cores (0.6 m each) were used for RNA ex-
traction using Trizol LS reagent (Invitrogen) as previously described
[6]. Five hundred nanograms of total RNA were used as starting ma-
terial for the reverse transcriptase (RT) reaction using the Omniscript
RT kit (Qiagen) following the manufacturer’s protocol. Fifty nano-
grams of the resulting cDNA template were used for polymerase
chain reaction (PCR) amplification using the Platinum Taq DNA
Polymerase kit (Invitrogen). All PCR reactions were performed using
the master mix, the Platinum Taq DNA Polymerase supplied in the
kit following the manufacturer’s protocol, and a final MgCl2 and
each PCR primer (Integrated DNA Technologies, Inc., Coralville,
IA) concentration of 1.5 and 0.2 mM, respectively. The reactions
were incubated at 94°C for 4 minutes for an initial denaturation step
followed by 45 cycles of 94°C for 30 seconds, with the annealing
temperature specific to the primer pair used (see below) for 30 sec-onds and elongation at 72°C for 1 minute. The reactions were then
incubated at 72°C for an additional 10 minutes. All PCR reactions
were performed using a DNA Engine Tetrad 2 Peltier Thermal Cycler
(Bio-Rad, Hercules, CA). Polymerase chain reaction products were frac-
tionated and visualized using an ethidium bromide (0.5 mg/ml; EMD
Chemicals, Gibbstown, NJ) containing 2.5% agarose (EMD Chemi-
cals) gel. Annealing temperatures for the ELM4-ALK fusion transcript
primers, downstream ALK primers and glyceraldehyde 3-phosphate de-
hydrogenase (GAPDH) were 55, 50, and 55°C, respectively.
In this RT-PCR assay, we used primers that target fusion variant 1
(as described in the study of Soda et al. [3]) which could also detect
variant 2 which would have yielded a considerably longer amplicon.
The latter variant may have been expressed in the fusion positive
cases but missed in our assay because of the difficulties in amplifying
long amplicons from RNA extracted from FFPE tissue.
The following are the forward and reverse primer sequences for: the
EML4-ALK fusion transcript variant 1: 5′-GTGCAGTGTTTAGCA-
TTCTTGGGG and 5′-TCTTGCCAGCAAAGCAGTAGTTGG,
respectively; 3′ ALK: 5′-TTGGAGAGAGGATTGAATACTGC and
5′-GACCAGGAGAGGAGGAACC, respectively; GAPDH: 5′-
TGCACCACCAACTGCTTAGC and 5′-GGCATGGACTGTGGT-
CATGAG, respectively. Independent PCR reactions were carried out
for each primer pair.
Study Populations
Tissue microarrays from the University of Zurich and the Univer-
sity of Michigan were used to access EML4 and ALK rearrangement
status. The University of Zurich cohort is a population based NSCLC
cohort of 507 patients. The University of Michigan cohort represents
a surgical series of 96 NSCLC patients. The samples were comprised
in high-density tissue microarrays with one to three cores representing
a case.Results
In the two NSCLC cohorts examined, 16 of 603 total cases exhib-
ited evidence for EML4 and/or ALK rearrangement by FISH. Rear-
rangement patterns included loss of the interstitial probes between
EML4 and ALK (Figure 1B), loss of the probes on 2p outside the
area encoding either EML4 or ALK (Figure 1C ), and break-apart
of the genes (Figure 1D). Thus, the frequency of EML4 and ALK
rearrangements that potentially result in EML4-ALK fusion is
2.7%. We found that for the majority of positive cases only a subset
of tumor cells (50-100%) harbored 2p rearrangements. We also
found evidence of focal high-level amplification of EML4 in five
cases and of ALK in three cases. The amplification was similar to
the recently reported NKX2-1 (TTF1) amplification pattern seen
in NSCLCs [5] (Figure 1E ). In two cases, we found high-level am-
plification of both EML4 and ALK, indicating a large-scale amplifi-
cation of the region including both loci. Only two cases showed
low-level amplification of one of the probes of the ALK break-apart
assay, indicating a simultaneous occurrence of rearrangement and
low-level amplification. No such event was observed with the EML4
break-apart assay.
We used RT-PCR to assess for the presence of the EML4-ALK var-
iant 1 fusion transcript and 3′ ALK transcript in eleven cases that
scored positive for EML4 and/or ALK rearrangement by FISH (Ta-
ble 1), as well as two cases (n1 and n2 in Figure 2) that showed no evi-
dence for rearrangement. We detected EML4-ALK variant 1 fusion
Table 1. Summary of EML4 and ALK Rearrangements by FISH as well as EML4-ALK Variant 1
Fusion Transcript and 3′ ALK Transcript by RT-PCR.
Case
No.
EML4 FISH ALK FISH RT-PCR
Del
Cent
Del
Tel
Break-
Apart
Del
Cent
Del
Tel
Break-
Apart
EML4-ALK
Variant 1 Fusion
Transcript
3′ ALK
1 − − − + − − − −
2 + − − + − − + +
3 + − − − − + + +
4 + − − − − − − −
5 − + − − − − − +
6 + − − − − − − −
7 − + − − − − − −
8 − − − − − + − −
9 − + − − − − − −
10 − + − + − − + +
11 − − − − + − N/A N/A
12 − + − + − − N/A N/A
13 − − − − + − N/A N/A
14 − − − + − − N/A N/A
15 + − − − − − N/A N/A
16 + − − − − − N/A N/A
RT-PCR data only available in cases where still tissue was available. Del Cent indicates loss of the
centromeric probe; Del Tel, loss of the telomeric probe; Break-Apart, break-apart of the two signals
of the FISH probes for the specific gene; N/A, samples not annotated by PCR because of the lack
of available material.
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rearrangement in both genes (case nos. 2, 3, and 10 in Table 1 and
Figure 2). Only one case with loss of the interstitial (telomeric) EML4
FISH probe showed 3′ ALK transcript but no variant 1 fusion tran-
script (case no. 5 in Table 1 and Figure 2). All other rearranged cases
(case nos. 1, 4, 6, 7, 8, and 9 in Table 1 and Figure 2) and the two non-
rearranged cases (case nos. n1 and n2 in Figure 2) did not yield detect-
able ELM4-ALK variant 1 fusion transcript nor the 3′ ALK–specific
PCR product (see Table 1 for details of rearrangement status, ELM4-
ALK variant 1 fusion, and 3′ ALK transcript detection).
We also assessed the two NSCLC cohorts for the recently described
NKX2-1 amplification status by FISH [5]. Of these, 35 cases (5.8%)
demonstrated NKX2-1 high-level amplification. Of note, all casesFigure 2. RT-PCR results of selected cases that were found to be
positive or negative for ELM4 and/or ALK rearrangement by FISH.
Primers specific to the ELM4-ALK variant 1 fusion transcript
(EML4-ALK, exon 6 of ELM4 and exon 20 of ALK1), downstream
ALK (3′ ALK, exons 28 and 29), and GAPDH were used in combina-
tion with PCR of cDNA derived from RNA extracted from FFPE tis-
sue of the indicated cases or of two cases (n1 and n2) that were
negative for rearrangements. Results from FISH of ELM4 or ALK
rearrangement are given below the case number. Positive indica-
tors of rearrangement were attributed to cases if break-apart and/
or deletion was observed for gene-specific FISH probes. Refer to
Table 1 for specifics for each case shown here. Fifty-nucleotide
fragment ladder (lane L) and sizes are shown to the left.showing evidence for EML4 and ALK rearrangements were mutually
exclusive to the cases showing NKX2-1 high-level amplification.
Discussion
Whereas the true frequency of EML4-ALK fusion events remains to
be determined, our FISH results from two independent population-
based cohorts (Zurich and Michigan), comprising more than 600 pa-
tients, suggest that the EML4-ALK fusion may be less frequent (2.7%)
than reported that by Soda et al. [3] (6.7%). Although ethnic or other
patient differences could account for the discrepancy in frequency,
Inamura et al. [7] also report a frequency of 3.4% of EML4-ALK fu-
sion by RT-PCR in a Japanese cohort of 221 lung cancer patients.
Based on the findings by our FISH assays, more complex cytogenetic
EML4/ALK alterations result in EML4-ALK fusion rather than by a
unique simple inversion as suggested by Soda et al. [3]. In most cases,
we observed that only one of the assessed genes exhibited rearrange-
ment, suggesting that other, potentially more common, fusion part-
ners exist. This would not be surprising, because in anaplastic large
cell lymphoma, ALK rearrangements involve at least 10 alternative
fusion partners in addition to NPM [4]. Proof of this hypothesis was
recently published by Rikova et al. [8], who have identified TFG as
an ALK fusion partner in NSCLC. We also observed the 3′ ALK prod-
uct in one case (sample no. 5) that was negative for the EML4-ALK
fusion variant 1 transcript, which may be an example of another
EML4-ALK fusion transcript variant or another fusion event involv-
ing other partners [3,8].
In addition, amplification of either EML4 or ALK could represent
an important mechanism of overexpression in NSCLCs, in spite of
the fact that such changes were not detected in a recently released
large single nucleotide polymorphism dataset [5], likely due to intra-
tumor lesion heterogeneity. It remains to be determined whether
these amplified genes contain additional oncogenic abnormalities as
in the case of epidermal growth factor receptor [9], or whether over-
expression of wild-type EML4 and/or ALK is itself tumorigenic.
From this and other studies, we conclude that a range of alterations
of 2p21-p23 occurs in NSCLCs. However, within a given tumor, not
all tumor cells (between 50% and 100%) harbor 2p rearrangements/
amplifications, indicating that they may represent late-stage aberrations
or different simultaneous coproliferation of clones within the tumor,
rather than as early clonal events as recently observed in TMPRSS2-
ETS prostate cancers [10]. While remaining to be proven, our obser-
vations support the hypothesis that 2p21-p23 alterations are a rare
acquired but not a driving molecular event in lung cancer develop-
ment and progression.
Furthermore, we found NKX2-1 (TTF1) high-level amplification
in almost 6% of NSCLCs. This is slightly less compared to the re-
sults of Weir et al. [5], who reported NKX2-1 high-level amplifica-
tion in ∼12% of adenocarcinomas of the lung. However, unlike the
study of Weir et al., our cohort is a mixture of adenocarcinomas (75%)
and squamous cell carcinomas (25%). More importantly, all cases
showing evidence for EML4 and ALK rearrangements were mutually
exclusive to the cases showing NKX2-1 high-level amplification, indi-
cating that these events are associated with two independent pathways
resulting in lung cancer formation/progression.
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